20197-97-1

Basic information

• Product Name: 2-CHLORO-6-METHOXYQUINAZOLIN-4(3H)-ONE
• Synonyms: 2-CHLORO-6-METHOXYQUINAZOLIN-4(3H)-ONE;2-chloro-6-Methoxy-3H-quinazolin-4-one;2-chloro-6-methoxyquinazolin-4(1H)-one
• CAS NO: 20197-97-1
• Molecular Formula: C₉H₇ClN₂O₂
• Molecular Weight: 210.62
• Mol File: 20197-97-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-CHLORO-6-METHOXYQUINAZOLIN-4(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-6-METHOXYQUINAZOLIN-4(3H)-ONE(20197-97-1)
• EPA Substance Registry System: 2-CHLORO-6-METHOXYQUINAZOLIN-4(3H)-ONE(20197-97-1)

Safety Data

• Hazardous Substances Data: 20197-97-1(Hazardous Substances Data)

Upstream product

• 105763-77-7 2,4-dichloro-6-methoxy-quinazoline 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 32618-84-1 6-Methoxyquinazolin-2,4-dione 

Downstream Products

• 769158-53-4 2-((2-chloro-6-methoxy-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 

Relevant articles and documents

SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF

The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses； wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.

Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.

Antihypertensive 2-amino-4(3H)-quinazolinones.

-